Bioxytran Stock

Bioxytran EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Bioxytran (BIXT) as of Aug 13, 2026 is -3.95. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -5.75 — a change of -31.25% (higher).

EV/FCF

-3.95

YoY

-31.25%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Bioxytran is 2026 -3.95 . EV/FCF (Enterprise Value to Free Cash Flow) of Bioxytran was 2025 -5.75 . It decreases by -31.25% higher compared to the previous year.
Access this data via the Eulerpool API

Bioxytran Stock analysis

What does Bioxytran do? Bioxytran Inc. is a US-based company specialized in the development of medical therapies based on the use of oxygen transport molecules. The company's patented platform technology focuses on the development of new innovative therapies for treating central nervous system disorders, cardiovascular diseases, and cancer treatment. The company was founded in 2014 by a group of scientists and entrepreneurs aiming to create a transformative medical product that improves oxygen transport in the body and enables the treatment of severe diseases. Bioxytran's platform is based on the use of perfluorocarbon compounds (PFCs) that have a strong affinity for oxygen and can bind and transport it in the blood. The company's business model is centered on the development and commercialization of new therapies to treat diseases such as stroke, heart attack, cancer, and even COVID-19. By improving oxygen transport in the body, Bioxytran aims to enhance the effectiveness of medical treatments and create new therapeutic possibilities. The company's focus areas include stroke treatment, where they have developed a technology that allows direct oxygen transport to the affected brain tissue, minimizing neural damage and enabling faster recovery. They have also developed a new type of heart attack treatment that aims to improve blood flow and eliminate oxygen deficiency in the heart, as well as another therapy option for patients suffering from acute heart attacks. In the field of cancer treatment, Bioxytran has a promising therapy in the pipeline based on PFCs that can selectively target cancer cells, potentially making chemotherapy more effective and patient-friendly. Overall, Bioxytran's goal is to develop medical therapies that have the potential to revolutionize the treatment of severe diseases. They offer a range of products and approaches that have the potential to improve the lives of many patients. In summary, Bioxytran Inc. is an emerging company in the field of medical therapies, driven by innovation and technological expertise. Their focus on developing high-potential products that improve oxygen transport in the body facilitates the treatment of severe diseases. With their various divisions and products, Bioxytran is able to address a broad spectrum of medical needs. Bioxytran is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioxytran stock

EV/FCF (Enterprise Value to Free Cash Flow) of Bioxytran is -3.95 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Bioxytran changed from -5.75 to -3.95, representing a -31.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Bioxytran since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Bioxytran with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Bioxytran

All Key Metrics — Bioxytran